TET2 mutations in secondary acute myeloid leukemias: A French retrospective study

Olivier Kosmider; Eric Delabesse; Véronique Mansat-De Mas; Pascale Cornillet-Lefebvre; Odile Blanchet; Alain Delmer; Christian Recher; Sophie Raynaud; Didier Bouscary; Franck Viguié; Catherine Lacombe; Olivier A. Bernard; Norbert Ifrah; François Dreyfus; Michaëla Fontenay

doi:10.3324/haematol.2011.040840

TET2 mutations in secondary acute myeloid leukemias: A French retrospective study

Olivier Kosmider, Eric Delabesse, Véronique Mansat-De Mas, Pascale Cornillet-Lefebvre, Odile Blanchet, Alain Delmer, Christian Recher, Sophie Raynaud, Didier Bouscary, Franck Viguié, Catherine Lacombe, Olivier A. Bernard, Norbert Ifrah, François Dreyfus, Michaëla Fontenay

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

34 Citations (Scopus)

Résumé

Ten-eleven translocation 2 (TET2) mutations have been involved in myeloid malignancies. This retrospective study aims at evaluating the frequency and impact of TET2 mutations in 247 secondary acute myeloid leukemia cases referred to as myelodysplasia-related changes (n=201) or therapy-related (n=46) leukemias. Mutation of at least one copy of the TET2 gene was detected in 49 of 247 (19.8%) patients who presented with older age, higher hemoglobin level, higher neutrophil and monocyte counts, and lower platelet count. TET2 mutations were significantly less frequent in therapy-related (8.7%) than myelodysplasia-related changes (22.3%; P=0.035) leukemias and strongly associated with normal karyotype (P<0.001). TET2 mutations did not significantly associate with NPM1, FLT3-ITD or FLT3-D835, WT1, or N- or K-RAS mutations. Complete remission was achieved in 57% of evaluable patients who had received intensive chemotherapy. In this group, TET2 mutations did not influence the complete remission rate or overall survival.

langue originale	Anglais
Pages (de - à)	1059-1063
Nombre de pages	5
journal	Haematologica
Volume	96
Numéro de publication	7
Les DOIs	https://doi.org/10.3324/haematol.2011.040840
état	Publié - 1 juil. 2011

Accès au document

10.3324/haematol.2011.040840

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Kosmider, O., Delabesse, E., Mansat-De Mas, V., Cornillet-Lefebvre, P., Blanchet, O., Delmer, A., Recher, C., Raynaud, S., Bouscary, D., Viguié, F., Lacombe, C., Bernard, O. A., Ifrah, N., Dreyfus, F., & Fontenay, M. (2011). TET2 mutations in secondary acute myeloid leukemias: A French retrospective study. Haematologica, 96(7), 1059-1063. https://doi.org/10.3324/haematol.2011.040840

@article{22b110b1303f4c5ea9ac534c88032cdc,

title = "TET2 mutations in secondary acute myeloid leukemias: A French retrospective study",

abstract = "Ten-eleven translocation 2 (TET2) mutations have been involved in myeloid malignancies. This retrospective study aims at evaluating the frequency and impact of TET2 mutations in 247 secondary acute myeloid leukemia cases referred to as myelodysplasia-related changes (n=201) or therapy-related (n=46) leukemias. Mutation of at least one copy of the TET2 gene was detected in 49 of 247 (19.8%) patients who presented with older age, higher hemoglobin level, higher neutrophil and monocyte counts, and lower platelet count. TET2 mutations were significantly less frequent in therapy-related (8.7%) than myelodysplasia-related changes (22.3%; P=0.035) leukemias and strongly associated with normal karyotype (P<0.001). TET2 mutations did not significantly associate with NPM1, FLT3-ITD or FLT3-D835, WT1, or N- or K-RAS mutations. Complete remission was achieved in 57% of evaluable patients who had received intensive chemotherapy. In this group, TET2 mutations did not influence the complete remission rate or overall survival.",

keywords = "Characteristics, Prognosis, Secondary AML, TET2 mutations",

author = "Olivier Kosmider and Eric Delabesse and {Mansat-De Mas}, V{\'e}ronique and Pascale Cornillet-Lefebvre and Odile Blanchet and Alain Delmer and Christian Recher and Sophie Raynaud and Didier Bouscary and Franck Vigui{\'e} and Catherine Lacombe and Bernard, {Olivier A.} and Norbert Ifrah and Fran{\c c}ois Dreyfus and Micha{\"e}la Fontenay",

year = "2011",

month = jul,

day = "1",

doi = "10.3324/haematol.2011.040840",

language = "English",

volume = "96",

pages = "1059--1063",

journal = "Haematologica",

issn = "0390-6078",

number = "7",

}

Kosmider, O, Delabesse, E, Mansat-De Mas, V, Cornillet-Lefebvre, P, Blanchet, O, Delmer, A, Recher, C, Raynaud, S, Bouscary, D, Viguié, F, Lacombe, C, Bernard, OA, Ifrah, N, Dreyfus, F & Fontenay, M 2011, 'TET2 mutations in secondary acute myeloid leukemias: A French retrospective study', Haematologica, VOL. 96, Numéro 7, p. 1059-1063. https://doi.org/10.3324/haematol.2011.040840

TY - JOUR

T1 - TET2 mutations in secondary acute myeloid leukemias

T2 - A French retrospective study

AU - Kosmider, Olivier

AU - Delabesse, Eric

AU - Mansat-De Mas, Véronique

AU - Cornillet-Lefebvre, Pascale

AU - Blanchet, Odile

AU - Delmer, Alain

AU - Recher, Christian

AU - Raynaud, Sophie

AU - Bouscary, Didier

AU - Viguié, Franck

AU - Lacombe, Catherine

AU - Bernard, Olivier A.

AU - Ifrah, Norbert

AU - Dreyfus, François

AU - Fontenay, Michaëla

PY - 2011/7/1

Y1 - 2011/7/1

N2 - Ten-eleven translocation 2 (TET2) mutations have been involved in myeloid malignancies. This retrospective study aims at evaluating the frequency and impact of TET2 mutations in 247 secondary acute myeloid leukemia cases referred to as myelodysplasia-related changes (n=201) or therapy-related (n=46) leukemias. Mutation of at least one copy of the TET2 gene was detected in 49 of 247 (19.8%) patients who presented with older age, higher hemoglobin level, higher neutrophil and monocyte counts, and lower platelet count. TET2 mutations were significantly less frequent in therapy-related (8.7%) than myelodysplasia-related changes (22.3%; P=0.035) leukemias and strongly associated with normal karyotype (P<0.001). TET2 mutations did not significantly associate with NPM1, FLT3-ITD or FLT3-D835, WT1, or N- or K-RAS mutations. Complete remission was achieved in 57% of evaluable patients who had received intensive chemotherapy. In this group, TET2 mutations did not influence the complete remission rate or overall survival.

AB - Ten-eleven translocation 2 (TET2) mutations have been involved in myeloid malignancies. This retrospective study aims at evaluating the frequency and impact of TET2 mutations in 247 secondary acute myeloid leukemia cases referred to as myelodysplasia-related changes (n=201) or therapy-related (n=46) leukemias. Mutation of at least one copy of the TET2 gene was detected in 49 of 247 (19.8%) patients who presented with older age, higher hemoglobin level, higher neutrophil and monocyte counts, and lower platelet count. TET2 mutations were significantly less frequent in therapy-related (8.7%) than myelodysplasia-related changes (22.3%; P=0.035) leukemias and strongly associated with normal karyotype (P<0.001). TET2 mutations did not significantly associate with NPM1, FLT3-ITD or FLT3-D835, WT1, or N- or K-RAS mutations. Complete remission was achieved in 57% of evaluable patients who had received intensive chemotherapy. In this group, TET2 mutations did not influence the complete remission rate or overall survival.

KW - Characteristics

KW - Prognosis

KW - Secondary AML

KW - TET2 mutations

UR - http://www.scopus.com/inward/record.url?scp=79959952948&partnerID=8YFLogxK

U2 - 10.3324/haematol.2011.040840

DO - 10.3324/haematol.2011.040840

M3 - Article

C2 - 21508122

AN - SCOPUS:79959952948

SN - 0390-6078

VL - 96

SP - 1059

EP - 1063

JO - Haematologica

JF - Haematologica

IS - 7

ER -